APLUSA launched a new syndicated study analyzing in post-transplant CMV (for both Solid Organ Transplant - SOT - and Hematopoietic Stem Cell Transplantation - HSCT -), with results expected at the end of March 2023. The study design includes both Awareness, Trial & Usage - ATU - questions and detailed anonymised patient charts.
The study has been designed to provide: • A market landscape (market penetration, use of diagnostics, level of use of prophylaxis, pre-emptive and curative therapies…) • Attitude and usage of CMV treatments in hospitals for transplant patients (current protocols in anti-viral treatment - focus R/R CMV viremia, image and awareness including products in development…) • Management of CMV patients in transplant (patient characteristics, market shares, treatment patterns, patient pathways…) • Market opportunities (product potential, opportunities for growth…)
Results will be available in the coming months. Would you be interested in receiving more details? We would be happy to set up a short exploratory meeting, or a longer more detailed presentation with one of our experts!